Exploration of baseline and early changes in neurocognitive characteristics as predictors of treatment response to bupropion, sertraline, and placebo in the EMBARC clinical trial.

Yuen-Siang AngGerard E BruderJohn G KeilpAshleigh RutherfordDaniel M AlschulerPia PechtelChristian A WebbThomas CarmodyMaurizio FavaCristina CusinPatrick J McGrathMyrna WeissmanRamin ParseyMaria A OquendoMelvin G McInnisCrystal M CooperPatricia DeldinMadhukar H TrivediDiego A Pizzagalli

Published in: Psychological medicine (2020)

These exploratory results warrant further scrutiny, but demonstrate that quick and non-invasive behavioral tests may have substantial clinical value in predicting antidepressant treatment response.

Keyphrases

clinical trial
double blind
major depressive disorder
phase iii
bipolar disorder
open label
phase ii
study protocol
placebo controlled